This study systematically explored the associations between GLP-1RAs and 12 common psychiatric and neurodevelopmental conditions using large-scale GWAS datasets, revealing protective effects against schizophrenia, anxiety disorders, bipolar disorder, bulimia nervosa, PTSD, and autism, with consistent findings across multiple databases for anxiety disorders, autism, and schizophrenia
Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity
Simultaneously, the emerging evidence for GLP-1 agonist neuroprotection suggests that Semaglutide itself contributes to brain health during weight loss
Blood tests may include full blood count (to exclude anaemia), renal and liver function, thyroid function tests, vitamin B12 and folate levels, and HbA1c to assess glycaemic control